Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744223 | 0.85 | GAA (0.56) | GAAALDH1A1PLK1HDAC2HDAC8 | |
| SCHEMBL4328062 | 0.81 | GAA (0.41) | GAAALDH1A1PLK1HDAC2HDAC8 | |
| SCHEMBL6625604 | 0.81 | LMNA (0.38) | GAAALDH1A1HDAC2HDAC6KMT2A | |
| SCHEMBL160621 | 0.81 | ALOX5 (0.41) | GAAALDH1A1HTTPOLB | |
| SCHEMBL8961339 | 0.79 | GAA (0.33) | GAAALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL7246452 | 0.79 | SMN1; SMN2 (0.36) | GAAALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL1476818 | 0.78 | KMT2A (0.41) | GAAALDH1A1KMT2AKDM4ENPC1 | |
| SCHEMBL18547962 | 0.78 | SMN1; SMN2 (0.43) | GAAALDH1A1PLK1HDAC2HDAC8 | |
| SCHEMBL730792 | 0.76 | ALB (0.41) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL16095595 | 0.76 | NPC1 (0.58) | GAAALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108174603-B | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators | 阿芮纳制药有限公司 | 2021-07-02 | — | — | CN | claimed |
| EP-3292114-B1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | claimed |
| CN-108174603-A | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators for the treatment or prevention of disorders related thereto | 阿芮纳制药有限公司 | 2018-06-15 | — | — | CN | claimed |
| EP-3292114-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | claimed |
| US-9676758-B2 | 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto | Arena Pharmaceutical, Inc. (US) | 2017-06-13 | — | — | US | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| US-20160318911-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | US | claimed |
| WO-2016176571-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | claimed |
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | claimed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | claimed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | claimed |
| CN-108174603-B | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators | 阿芮纳制药有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3292114-B1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-105164142-B | Mannose Derivatives for the Treatment of Bacterial Infections | 沃泰克斯药物股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | GAA 1438/4885ALDH1A1 373/4885PLK1 3480/4885 |
| US-20160318911-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | GPR52, HTR2A, HTR2C | GAA 1191/4885ALDH1A1 1062/4885PLK1 2130/4885 |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | GAA 4833/4885ALDH1A1 3485/4885PLK1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.